{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:54:58Z","timestamp":1789923298287,"version":"4.0.1"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Antibiotic dosing in septic shock patients poses a challenge for clinicians due to the pharmacokinetic (PK) variability seen in this patient population. Piperacillin-tazobactam is often used for empirical treatment, and initial appropriate dosing is crucial for reducing mortality. Accordingly, we determined the pharmacokinetic profile of piperacillin (4 g) every 8 h, during the third consecutive dosing interval, in 15 patients treated empirically for septic shock. We developed a population pharmacokinetic model to assess empirical dosing and to simulate alternative dosing regimens and modes of administration. Time above the MIC (\n            <jats:italic>T<\/jats:italic>\n            &gt;MIC) predicted for each patient was evaluated against clinical breakpoint MIC for\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Pseudomonas aeruginosa<\/jats:named-content>\n            (16 mg\/liter). Pharmacokinetic-pharmacodynamic (PK\/PD) targets evaluated were 50%\n            <jats:italic>fT<\/jats:italic>\n            &gt;4\u00d7MIC and 100%\n            <jats:italic>fT<\/jats:italic>\n            &gt;MIC. A population PK model was developed using NONMEM, and data were best described by a two-compartment model. Central and intercompartmental clearances were 3.6 liters\/h (relative standard error [RSE], 15.7%) and 6.58 liters\/h (RSE, 16.4%), respectively, and central and peripheral volumes were 7.3 liters (RSE, 11.8%) and 3.9 liters (RSE, 9.7%), respectively. Piperacillin plasma concentrations varied considerably between patients and were associated with levels of plasma creatinine. Patients with impaired renal function were more likely to achieve predefined PK\/PD targets than were patients with preserved or augmented renal function. Simulations of alternative dosing regimens showed that frequent intermittent bolus dosing as well as dosing by extended and continuous infusion increases the probability of attaining therapeutic plasma concentrations. For septic shock patients with preserved or augmented renal function, dose increment or prolonged infusion of the drug needs to be considered. (This study has been registered at ClinicalTrials.gov under registration no. NCT02306928.)\n          <\/jats:p>","DOI":"10.1128\/aac.01347-15","type":"journal-article","created":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T02:21:18Z","timestamp":1441765278000},"page":"7018-7026","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":35,"title":["Population Pharmacokinetics of Piperacillin in the Early Phase of Septic Shock: Does Standard Dosing Result in Therapeutic Plasma Concentrations?"],"prefix":"10.1128","volume":"59","author":[{"given":"Kristina","family":"\u00d6brink-Hansen","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus Vestergaard","family":"Juul","sequence":"additional","affiliation":[{"name":"Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete","family":"Storgaard","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne Kragh","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Aarhus University Hospital, Skejby, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore Forsingdal","family":"Hardlei","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Brock","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Kreilgaard","sequence":"additional","affiliation":[{"name":"Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Gjedsted","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Medicine, Aarhus University Hospital, Skejby, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-012-2769-8"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/379825"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000098031.24329.10"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X0203000203"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc9091"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.01.015"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000217961.75225.E9"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.5.3.365"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318180fe62"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.12.009"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00294-06"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf130"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.10.002"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.10.008"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181968e44"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.027"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-013-3088-4"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-014-3403-8"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu027"},{"key":"e_1_3_2_21_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2013. Clinical breakpoints. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 16 April 2015."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1208\/ps040427"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:JOPA.0000034404.86036.72"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018828709196"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2004.00600.x"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.028"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.12.017"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00521-12"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201505-0857OC"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/510590"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.10.025"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.01.007"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2327-2332.2002"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-013-3187-2"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.06.008"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt523"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.10.2351"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jac\/41.suppl_4.43","article-title":"Beta-lactam\/beta-lactamase inhibitor combinations: pharmacodynamic considerations and possible role in the management of bacterial infections in the neutropenic host","volume":"41","author":"Okereke C","year":"1998","unstructured":"Okereke C, Dudley MN. 1998. Beta-lactam\/beta-lactamase inhibitor combinations: pharmacodynamic considerations and possible role in the management of bacterial infections in the neutropenic host. J Antimicrob Chemother 41(Suppl D):43\u201349.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02089-13"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4718-4724.2004"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki243"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-015-0276-3"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01347-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01347-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:38:56Z","timestamp":1645483136000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01347-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1128\/AAC.01347-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.01347-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"2015-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-08-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}